Phase II Clinical Trial to Assess the dose-response and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (MSCs) in Severe Renal Systemic Lupus Erythematosus (SLE).
No linked publications found in PubMed
Inclusion Criteria: * Fulfilling 1997 updated American College of Rheumatology (ACR) Criteria or 2012 SLICC Classification Criteria for SLE * Seropositive for antinuclear (≥1:80) and/or anti-DNA antibodies * Fulfilling following criteria for active renal disease: Class III or IV proliferative disease (ISN/RPS) Renal Biopsy within 12 months plus... Active Urinary Sediment (\> 5 red blood cells/high-power field and/or \>8 white blood cells/high-power field and/or cylindruria during the current flare). UPC ratio ≥ 1 Exclusion Criteria: * Estimated GFR \< 40ml/min/m2 * Addition during prior 3 months of randomization of: Bolus methylprednisolone or new immunosuppressive drug or intravenous immunoglobulin (IVIG) or Plasmapheresis. * Addition during prior 6 months of randomization of Cyclophosphamide * Addition during prior 12 months of randomization of Biological anti-B cell therapy * Coexisting uncontrolled morbidity; Pregnancy or planned Pregnancy within next 12 months; uncontrolled infection or neoplastic disease. Pending unresolved surgical indication.